Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Altimmune (NASDAQ:ALT) announced its earnings results on Tuesday. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03, Zacks reports. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same period in the previous year, the firm earned ($0.39) earnings per share.

Altimmune Trading Down 11.2 %

Shares of ALT stock traded down $1.06 during trading hours on Thursday, hitting $8.46. 5,127,731 shares of the company were exchanged, compared to its average volume of 3,864,876. Altimmune has a 52-week low of $2.34 and a 52-week high of $14.84. The firm has a fifty day simple moving average of $6.99 and a 200 day simple moving average of $6.90. The stock has a market capitalization of $600.91 million, a price-to-earnings ratio of -5.45 and a beta of 0.09.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ALT shares. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Thursday. B. Riley restated a “buy” rating and set a $20.00 price objective on shares of Altimmune in a research note on Monday, August 12th. Evercore ISI raised Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Finally, UBS Group started coverage on Altimmune in a research report on Tuesday. They set a “buy” rating and a $26.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the sale, the director now owns 41,958 shares in the company, valued at $289,510.20. This trade represents a 27.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.